Literature DB >> 19626158

Advanced gastric cancer: a disease of diverse clinical biology.

Yixing Jiang1.   

Abstract

Entities:  

Year:  2009        PMID： 19626158      PMCID： PMC2713139     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  9 in total

1.  Patient with advanced gastric cancer responds twice to the same systemic therapy.

Authors:  Rachel Lagaly; Ashley Horak; Jeffrey H Lee; Paul F Mansfield; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2009-05

2.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

Authors:  A Webb; D Cunningham; J H Scarffe; P Harper; A Norman; J K Joffe; M Hughes; J Mansi; M Findlay; A Hill; J Oates; M Nicolson; T Hickish; M O'Brien; T Iveson; M Watson; C Underhill; A Wardley; M Meehan
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

3.  A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.

Authors:  Sung Yong Oh; Hyuk-Chan Kwon; Bong-Gun Seo; Sung-Hyun Kim; Jae-Seok Kim; Hyo-Jin Kim
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

Review 4.  The epidemiology of gastric cancer.

Authors:  David M Roder
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

5.  Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.

Authors:  Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Cindy Marabotti; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

6.  Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

Authors:  A F C Okines; A R Norman; P McCloud; Y-K Kang; D Cunningham
Journal:  Ann Oncol       Date:  2009-05-27       Impact factor: 32.976

Review 7.  Gastric cancer: epidemiology, pathology and treatment.

Authors:  S R Alberts; A Cervantes; C J H van de Velde
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

8.  Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

Authors:  Yeon Hee Park; Jae-Lyun Lee; Baek-Yeol Ryoo; Min-Hee Ryu; Sung Hyun Yang; Bong Seog Kim; Dong Bok Shin; Heung Moon Chang; Tae Won Kim; Young Jin Yuh; Yoon-Koo Kang
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-24       Impact factor: 3.333

9.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia.

Authors:  W J Blot; S S Devesa; R W Kneller; J F Fraumeni
Journal:  JAMA       Date:  1991-03-13       Impact factor: 56.272
  9 in total
  1 in total

1.  A challenging diagnosis: Case report of oral metastasis from gastric adenocarcinoma mimicking pyogenic granuloma.

Authors:  Ciro Dantas Soares; Breno Amaral Rocha; Lívia Máris Ribeiro Paranaiba; Mário Rodrigues de Melo-Filho; Jacks Jorge; Maria Goretti Freire de Carvalho; Oslei Paes de Almeida
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.